HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by van der Ent, C. K Articles by Rijkers, G. T Search for Related Content PubMed PubMed Citation Articles by van der Ent, C. K Articles by Rijkers, G. T

Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody

¹ Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, Utrecht, The Netherlands
² Department of Pediatrics, Hieronymus Bosch Hospital, Hertogenbosch, The Netherlands
³ Department of Pediatric Immunology, University Medical Center Utrecht, Utrecht, The Netherlands

Correspondence to:
Correspondence to:
Dr C K van der Ent
Department of Pediatric Respiratory Diseases, University Medical Center Utrecht, KH 01.419.0, PO Box 85090, 3508 AB Utrecht, The Netherlands; k.vanderent{at}wkz.azu.nl

Allergic bronchopulmonary aspergillosis (ABPA) can cause severe worsening of the respiratory condition in patients with cystic fibrosis. Treatment can result in steroid dependency and serious adverse events. A dramatic and rapid improvement of respiratory symptoms and lung function after a single dose of anti-IgE antibody (omalizumab) in a 12-year-old girl with cystic fibrosis and ABPA is described. This is the first report of this experimental treatment. It suggests an important role for IgE in the pathogenesis of ABPA and offers new therapeutic possibilities.